Liraglutide Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 3 mg/mL
Reference Brands: Saxenda(US & EU)
Category:
Weight Loss drugs
Saxenda (liraglutide 3 mg) is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and increases satiety. It supports weight loss, improves metabolic health, and helps manage obesity. Benefits include appetite suppression, significant weight reduction, improved blood sugar control, and enhanced overall wellness.
Liraglutide injection is available in Injection
and strengths such as 3 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Liraglutide injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Liraglutide injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Saxenda (liraglutide 3 mg) is approved in the US by the FDA and in the EU via EMA for chronic weight management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews trial and quality data promptly, while EMA ensures regional safety and manufacturing compliance. For dossier preparation, regulatory pathways, and market access guidance, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and global availability, helping patients worldwide achieve significant weight loss and metabolic health improvements through high-quality Saxenda therapy supported by regional regulations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing